In today’s fast-evolving pharma landscape, competitive intelligence (CI) teams are uniquely positioned to influence strategic decisions across the business. But with multiple stakeholders, therapeutic areas, and shifting priorities, how can CI leaders ensure their insights consistently drive value? Our latest executive summary explores the most common pitfalls that hinder CI effectiveness—and offers practical, actionable strategies […]
Share:
In today’s fast-evolving pharma landscape, competitive intelligence (CI) teams are uniquely positioned to influence strategic decisions across the business. But with multiple stakeholders, therapeutic areas, and shifting priorities, how can CI leaders ensure their insights consistently drive value?
Our latest executive summary explores the most common pitfalls that hinder CI effectiveness—and offers practical, actionable strategies to overcome them.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
